Mavacamten
Mavacamten is a prescription medication used to treat symptomatic obstructive hypertrophic cardiomyopathy (HCM) in adults. It works as a selective, reversible inhibitor of cardiac myosin, reducing the heart's ability to contract forcefully and helping improve symptoms. This medication is specifically indicated for patients who continue to experience symptoms despite standard treatments.
Mavacamten is a cardiac myosin inhibitor used to treat symptomatic obstructive hypertrophic cardiomyopathy by reducing excessive heart muscle contraction.
This medication carries a boxed (black box) warning — the strongest type of FDA warning. Review the full prescribing information before use.
Key facts at a glance
- ATC
- C01EB24
- RxNorm
- 2600867
- Generic
- Mavacamten
- Class
- atc-c01
- Brands
- Camzyos
- Availability
- rx
- Lactation
- unknown
- Routes
- oral
- Forms
- capsule
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Treatment of symptomatic obstructive hypertrophic cardiomyopathy (HCM) in adults who have NYHA Class II-III symptoms, to improve exercise capacity and symptoms.
Mavacamten is an allosteric and reversible inhibitor selective for cardiac myosin. It modulates the number of myosin heads that can enter 'on actin' (power-generating) states, reducing the probability of force-producing (systolic) and residual (diastolic) cross-bridge formation, thereby decreasing excessive cardiac contractility.
Requires echocardiographic monitoring for left ventricular ejection fraction (LVEF). Use is contraindicated in patients with LVEF <55%. May cause heart failure exacerbation in those with markedly elevated LVEF gradients at rest. Pregnancy should be avoided during treatment due to potential fetal harm. Drug interactions with CYP2C19 and CYP3A4 inhibitors require dose adjustment.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy